# Cannabis Is Not Vascularly Inert: Proatherogenic Inflammation in Youth > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-is-not-vascularly-inert-proatherogenic-inflammation-in-youth/ > **Published:** 2026-08-15T12:14:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:12:08-04:00 > **Clinical Summary:** Cannabis vascular inflammation in youth drives proatherogenic monocyte activation. Clinical implications for cardiovascular risk counseling. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyPediatricsNeurology[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)CBDTHC Why This Matters Clinicians need to counsel young cannabis users about potential cardiovascular risks, particularly regarding inflammation and atherosclerosis development, as emerging evidence suggests [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may promote vascular dysfunction beyond previously assumed safety profiles. This research highlights that cannabis affects vascular biology in youth during critical periods of atherosclerotic plaque formation, making it relevant for preventive counseling and risk stratification in primary care and cardiology settings. Clinical Summary This editorial highlights emerging evidence that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), particularly in young people, may promote atherosclerotic disease through proinflammatory vascular mechanisms rather than being hemodynamically neutral as previously assumed. The authors emphasize that cannabis-induced activation of monocytes and inflammatory pathways can accelerate vascular changes associated with atherosclerosis development, suggesting that the cardiovascular risk profile of cannabis differs substantively from prior characterizations. This finding is particularly concerning given increasing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) among adolescents and [young adults](https://cedclinic.com/young-adult-substance-use-hidden-brain-costs/) during a critical window for cardiovascular risk factor accumulation. Clinicians should recognize that cannabis use may contribute to long-term vascular disease risk through inflammatory mechanisms independent of acute hemodynamic effects, warranting discussion of cardiovascular risks during [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/) about cannabis use. When counseling young patients considering or actively using cannabis, physicians should incorporate discussion of potential atherosclerotic risk alongside other known cardiovascular effects to support informed decision-making about cannabis consumption. Dr. Caplan’s Take “This editorial raises important questions about cannabis and vascular inflammation that deserve serious attention, but I’d caution that an editorial itself isn’t the primary evidence—we need to see the underlying research it’s discussing and ideally prospective studies in human populations to understand the clinical magnitude of any risk, particularly in young people where vascular trajectories are still forming.” Clinical Perspective 💚 This editorial raises important concerns about cannabis use and vascular health in young people, highlighting potential proatherogenic inflammatory pathways involving monocyte activation that challenge the notion that cannabis is cardiovascularly benign. While the mechanistic evidence for cannabis-induced vascular inflammation appears compelling, clinicians should recognize that most of this work remains in early-stage research with limited long-term human outcome data, and that confounders such as smoking method, frequency of use, concurrent tobacco exposure, and underlying cardiovascular risk profiles complicate interpretation of causality. Additionally, the generalizability of findings in youth populations to other age groups or to different cannabis preparations (smoked versus ingested) remains unclear. Nevertheless, given the rising prevalence of cannabis use among adolescents and [young adults](https://cedclinic.com/young-adult-substance-use-hidden-brain-costs/) at a critical window for atherosclerotic development, clinicians should incorporate detailed cannabis use history into cardiovascular risk assessments, counsel patients—especially those with existing risk factors—about 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Is%20Not%20Vascularly%20Inert%3A%20Proatherogenic%20Inflammation%20in%20Youth%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73489)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73489)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Is%20Not%20Vascularly%20Inert%3A%20Proatherogenic%20Inflammation%20in%20Youth%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73489)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/42594172/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=1ncuFVMRo4HvVSDxkE8buGo0yxkEmrUpESaASXF7OZZyMEfQCn&fc=None&ff=20260815080924&v=2.20.1](https://pubmed.ncbi.nlm.nih.gov/42594172/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=1ncuFVMRo4HvVSDxkE8buGo0yxkEmrUpESaASXF7OZZyMEfQCn&fc=None&ff=20260815080924&v=2.20.1) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).